Analysis

Last week, we attended CBI’s 9th Annual Trade and Channel Strategies conference in Philadelphia, Pennsylvania. The keynote speaker was none other than Adam J. Fein, Ph.D.

Dr. Fein and others pointed out that manufacturer trade activities must evolve into an integrated channel strategy commercial function.

Below, we summarize other key takeaways from the meeting, including alternative distribution strategies, the outlook for buy-and-bill, and the emergence of boundary-spanning organized customers.

Posted by Drug Channels on Wednesday, December 18, 2013

Labels: Specialty Drugs, Channel Management, Hospitals, 340B, Pharmacy Economics

The Pharmacy Benefit Management Institute (PBMI) has just released its 2013-2014 Prescription Drug Benefit Cost and Plan Design Report. (Free download.) This report provides invaluable insight into employer-sponsored pharmacy benefits. Drug Channels again salutes Takeda Pharmaceuticals North America for having sponsored the research.

As far as I know, the PBMI report offers the only public benchmarking data on manufacturer rebates to pharmacy benefit managers (PBMs). A few highlights:

• Employers use a wide variety of rebate structures, including per-prescription guarantees and percentage shares. Nearly one-third of smaller employers get no rebates.

• Rebates average $17 per 30-day brand-name retail prescriptions. Surprisingly, rebates were comparable for both large and small employers.

• On average, PBMs pass more than 80% of rebates back to employers.

Read on for details from the report. And don’t forget to join me at the PBMI’s Annual Drug Benefit Conference in February.

Posted by Drug Channels Institute, an HMP Global company on Monday, December 16, 2013

Labels: Costs/Reimbursement, PBMs, Benefit Design

According to a new must-read Bloomberg story, Express Scripts plans to start a price war over new hepatitis C treatments. The news follows the release of Gilead’s Sovaldi (sofosbuvir), which reportedly costs $1,000 per pill.

Express Scripts projects that Hepatitis C drug trend will grow by 168% by 2015, so payers are closely watching this test case. When there are multiple treatments in a therapeutic class, can the biggest PBM really control specialty drug costs?

While Express Scripts is talking boldly, the empty threat of blocking valuable medications has come back to life more times than a narcoleptic Jason Voorhees.

Read on for details on the unlucky hepatitis C medications that may be cut (or not) by Express Scripts’ machete.

Posted by Drug Channels Institute, an HMP Global company on Friday, December 13, 2013

Labels: Specialty Drugs, Benefit Design, PBMs

If you can’t beat ‘em…

Yesterday, Cardinal Health (NYSE: CAH) and CVS Caremark (NYSE: CVS) announced a new 50/50 generic drug buying joint venture. See CVS Caremark And Cardinal Health Announce Creation Of Largest Generic Sourcing Entity In U.S.

Shocking? Not really. As I noted in Quantifying Generic Buying Power for McKesson-Celesio, big deals have a funny way of spawning more deals. Et tu, Express Scripts?

The joint venture structure and deal terms make it a win-win for CVS Caremark and Cardinal. Both companies will gain significant scale going into the upcoming wave of newly-generic drugs. Read on for the details and comments on the new joint venture structure.

Posted by Drug Channels Institute, an HMP Global company on Wednesday, December 11, 2013

Labels: Wholesalers, Generic Drugs, Channel Management, Pharmacy

There have been three major specialty pharmacy announcements over the last week.

• Long term care pharmacy Pharmerica acquired a minority stake in fast-growing specialty pharmacy Onco360

• Express Scripts opened up its specialty pharmacy network to physicians in the RainTree Oncology network

• Grocery chain Giant Eagle bought Rx21, a small transplant/hepatitis C specialty pharmacy

Pay attention. As these deals show, the specialty market is getting even hotter. Everyone wants specialty drug revenue. Read on to find out who’s moving in.

Posted by Drug Channels on Tuesday, December 10, 2013

Labels: Specialty Drugs, Mergers and Acquisitions, Pharmacy

Today’s guest post is from George Kitchens, RPh, President of Artia Solutions, and consultant for Elsevier.

In this new post, Kitchens revisits the topic of drug price transparency and discusses how Predictive Acquisition Cost (PAC) helps ensure accurate reimbursement rates for both pharmacies and payers. To learn more, download Elsevier’s most recent report on PAC use cases across the industry, entitled Achieving Cost Savings with Accurate Drug Price Information: Industry Use Cases for PAC.

Please contact George Kitchens (gkitchens@artiasolutions.com) with any questions about the article.

Posted by Drug Channels on Monday, December 9, 2013

Labels: Sponsored Post, Guest Post

Great news! You can now find more fresh information tidbits on the Drug Channels Twitter page.

At our page, @DrugChannels, you’ll find our carefully curated, hand-crafted selection of news and opinions about drug distribution, pharmaceutical economics, reimbursement, payers, current events, and more.

Follow us to learn about the events we attend, get up-to-the-minute news via live tweets, and view fun photos of us in action.

Sample tweets below. Enjoy!

Posted by Drug Channels on Friday, December 6, 2013

Labels: Blog Administration

While you were busy brining a turkey last week, CVS Caremark purchased Coram LLC, the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group. Read the press release.

I spot three factors behind the deal:

• Home infusion is a fast-growing channel for specialty drugs, so the deal deepens CVS/pharmacy’s footprint as a major dispensing channel. CVS can also catch up to Walgreens.

• Home infusion can be a cheaper site of care, which helps Caremark’s specialty benefit management PBM business. Oddly, CVS Caremark’s own data shows home infusion to be more expensive than in-office treatment. See the chart below.

• Benefit coverage for home infusion specialty drugs is fragmented across the pharmacy and medical benefits. Payers are therefore looking for integrated management, visibility, and control.

Read on for details and background, some of which appeared a mere two weeks ago in CVS Caremark’s 2013 specialty trend report. CVS Caremark continues to expand throughout the healthcare system, swallowing up adjacent sectors with ease.

Posted by Drug Channels Institute, an HMP Global company on Thursday, December 5, 2013

Labels: Specialty Drugs, Mergers and Acquisitions, Channel Management, PBMs, Pharmacy

Ever wonder why cancer care costs so much more in a hospital than in a doctor’s office? A Milliman, Inc., study—Comparing Episode of Cancer Care Costs in Different Settings: An Actuarial Analysis of Patients Receiving Chemotherapy—has an answer. (Free download).

The report compared cancer treatment costs in outpatient hospital departments vs. outpatient physician offices. As we highlight below, hospitals inflate drug expenses far beyond acquisition costs.

• For treatment in a physician office, total drug costs range from $12,000 to $62,000.

• For treatment in a hospital outpatient setting, total drug costs range from $18,000 to $91,000.

• The markups are especially egregious for such higher-cost specialty drug therapies as cytotoxic chemotherapies and biologics.

Once again, we see that hospitals can generate more revenue from specialty drug administration than can independent physician-owned clinics. Drug channel intermediaries can add to drug prices, with different markups for different channels.

Read on to see how shopping for cancer drugs in a hospital setting can bag you a very bum deal.

Posted by Drug Channels on Tuesday, December 3, 2013

Labels: Specialty Drugs, Hospitals, Costs/Reimbursement, Industry Trends

Check out this cool conference: The Pharmacy Benefit Management Institute (PBMI) will host its 19th Annual Drug Benefit Conference at the Paris Hotel in Las Vegas, on February 3-5, 2014.

Many attendees will be from employers, health plans, and unions, so you’ll learn the payers' perspectives on pharmacy benefits. Highlights include multiple sessions on specialty drug management as well as the latest techniques for pharmacy benefit manager oversight. Check out the session descriptions.

Register before January 10, 2014, to get the early bird rates. Drug Channels readers can register with promo code PC2014 and receive an additional $300 off registration. Thanks, PBMI!

I’ll be attending, but not presenting. See you in Las Vegas.

Posted by Drug Channels Institute, an HMP Global company on Monday, December 2, 2013

Labels: Sponsored Post